Strategies & Technologies Driving Drug Discovery to Market
Subscribe to Drug Discovery & Development All

RA Patients Seek Treatment Later Than Sooner

September 2, 2011 7:58 am | News | Comments

A study reveals that patients wait 18 months after first experiencing any symptoms of rheumatoid arthritis (RA) before going to see their doctor.


SuperGen to Change Name and Symbol

September 2, 2011 7:54 am | News | Comments

SuperGen Inc. will begin operating under the name Astex Pharmaceuticals Inc. on Sept. 12, 2011.


OXiGENE Announces Restructuring

September 2, 2011 7:50 am | News | Comments

OXiGENE Inc. announced a restructuring plan designed to focus the company's capital resources on its early-stage clinical programs and further reduce its cash utilization.


Oxygen Deprivation May Block Fetal Brain Damage

September 2, 2011 7:45 am | News | Comments

Examining brain damage that occurs when fetuses in the womb are deprived of oxygen, researchers at The Scripps Research Institute have discovered that damage does not occur randomly but is linked to the specific action of a naturally occurring fatty molecule called LPA, acting through a receptor that transfers information into young brain cells.


Malaria Discovery Gives Hope for New Vaccine

September 2, 2011 7:42 am | News | Comments

An investigation into the mysterious inner workings of the malaria parasite revealed that it survives and proliferates in the human bloodstream thanks in part to a single, crucial chemical that the parasite produces internally.


Leukemia Stem Cells Predict Clinical Outcomes

September 2, 2011 7:34 am | News | Comments

Cancer scientists have long debated whether all cells within a tumor are equal or whether some cancer cells are more potent: a question that has been highly investigated in experimental models in the last decade.


Chemists Modify Sea Bacteria Byproduct for Drug Use

September 2, 2011 7:30 am | News | Comments

University of Florida researchers have modified a toxic chemical produced by tiny marine microbes and deployed it against laboratory models of colon cancer.


Endotoxin Removal

September 2, 2011 6:57 am | Product Releases | Comments

G-Biosciences EndotoxinOUT is designed to remove endotoxins from buffers, cell culture media, protein solutions, nucleic acid samples, and pharmacological components.


FTIR Spectroscopy

September 2, 2011 6:53 am | Product Releases | Comments

Mettler Toledo announces the availability of a Fourier transform infrared spectroscopy instrument, FlowIR. As one of the smallest FTIR instruments, FlowIR can be placed nearly anywhere along a reactor setup.


Aridhia And Glencoe Partner on Informatics

September 2, 2011 6:43 am | News | Comments

Aridhia Informatics Ltd and Glencoe Software have formed a strategic partnership to create innovative products to aid the development of personalized therapies and deliver improved patient outcomes.


Kuros Completes Phase 2 Trial Enrollment

September 2, 2011 6:29 am | News | Comments

Kuros Biosurgery AG announced that it has completed recruitment in a Phase 2b clinical trial designed to investigate KUR-211 in the treatment of diabetic foot ulcers.


IST Granted LMA Patent

September 2, 2011 6:25 am | News | Comments

Immune System Therapeutics Limited announced it had secured patent protection for a new method of treating blood cancers that express a target called lambda myeloma antigen.


Signals Found to Preserve Antiviral Antibodies

September 2, 2011 6:21 am | News | Comments

Our immune system is capable of a remarkable feat: the ability to remember infections for years, even decades, after they have first been encountered and defeated.


New HIV Vax Targets Desirable Immune Cells

September 2, 2011 6:10 am | News | Comments

Researchers have demonstrated an approach to HIV vaccine design that uses an altered form of HIV's outer coating or envelope protein. The design could bind better to immature B cell receptors creating an enhanced immune response.


More Extensions in Pfizer's Icagen Bid

September 2, 2011 6:04 am | News | Comments

Drugmaker Pfizer Inc. for a second time is extending its tender offer for pain drug developer Icagen, as the number of shares tendered again fell short of what Pfizer needed.



You may login with either your assigned username or your e-mail address.
The password field is case sensitive.